InvestorsHub Logo
Followers 37
Posts 4190
Boards Moderated 0
Alias Born 10/18/2016

Re: None

Friday, 02/09/2018 9:23:35 AM

Friday, February 09, 2018 9:23:35 AM

Post# of 394
Compensated Awareness Post View Disclaimer
PRVCF Advancing Work on Novel Delivery for Cannabinoid Therapies

A partnership between health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Australia’s UniQuest Pty Limited aimed at furthering research and development of a soluble gel is working toward a novel means of delivering cannabinoids to the central nervous system directly from the nasal cavity in order to treat pain, inflammation, seizures and neurological disorders. The partnership is taking advantage of the growing legalization of medical marijuana throughout the world amid increasing evidence of cannabinoids’ benefits. An article discussing this reads: “The global nasal drug delivery technology market is projected to reach $64 billion by 2021, expanding at a compound annual growth rate of 6.5 percent, according to a report issued by MarketsandMarkets (http://nnw.fm/usd0S). While the report is segmented based on dosage form, therapeutic application, end user, system, container and region, it also states ‘intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.’”

To view the full article, visit http://nnw.fm/S7SQn

About PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PRVCF News